Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Aditi Singhai
Alison Sathe
Anders Vinther
Anne-Caroline Boillot
Barbara W. Unger
Barry Price
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Khushboo Agrawal
Mark Agostino
Michael de la Torre
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Tashil Sharma
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Delay, Denial, or Limiting of Inspections Since 2008

No items found.

Assessing Your Readiness State for FSMA: Stabilize, Then Benchmark

No items found.

The Story of 3 Consent Decrees

No items found.

EU vs. FDA: My Inspectors are More Rigorous Than Yours

No items found.

5 Features to Look for in an EIR

EIR
EIRs

To Understand Data Integrity, Just Read These 6 FDA 483s

No items found.

Welcome to the new FDAzilla.com

No items found.

5 FEATURES TO LOOK FOR IN A WARNING LETTER

No items found.

Does an FDA Import Alert automatically equate to an impending FDA Warning Letter?

No items found.

Data Integrity and Enforcement Actions

No items found.

Data Integrity: The Whole Story

No items found.

4 Trends About GMP Inspection Readiness and FDA Data Intelligence

No items found.

Everything you’ve ever wanted to know about how FDA 483s are written

No items found.

8 Key cGMP Areas FDA Inspectors Seem to Focus On

No items found.

Dinner in Costa Rica with an FDA inspector (and his wife)

No items found.

Seven Success Criteria for Hiring (and working with) a Good GMP Consultant

No items found.

Top 10 Responsibilities of the Pharma Quality Unit

No items found.

Dangerous Documents: Avoiding Land Mines in Your Emails and Documents | July 28, 2011

No items found.